
Research peptides
PE-22-28
PE-22-28 is a seven-amino-acid peptide designed as a shortened analogue of spadin, a 17-amino-acid peptide derived from the propeptide of sortilin (neurotensin receptor 3). Later papers from the same group also call it mini-spadin.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot PE2228-0528: 99.90% purity (RP-HPLC), 10.21 mg measured, identity confirmed by mass spec. Issued 2026-06-17 by Bioviridian Inc.. Verify certificate COA4859
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- TREK-1 potassium channel pharmacology
- Mouse behavioral models of depression
- Hippocampal neurogenesis and synaptogenesis
- Stroke and post-stroke depression in mice
How it is thought to work
The proposed mechanism is block of the TREK-1 two-pore-domain potassium channel. In patch-clamp studies on cells expressing human TREK-1, PE-22-28 showed a reported IC50 of 0.12 nM, against 40 to 60 nM for spadin. A later study from the same group described a biphasic action, with channel activity increased at low concentrations and inhibited at higher ones.
Where the research stands
Preclinical research. Published data are limited to cell and mouse studies from a single French research group. No human trial was found on ClinicalTrials.gov, and it is not an approved medicine.
Sources
- Mazella J, et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biology.
- Djillani A, et al. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology.
- Mazella J, et al. (2018). The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1. Frontiers in Pharmacology.
- Pietri M, et al. (2019). First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology.
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
